These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 16783999

  • 1. [New steps towards an influenza A vaccine].
    Nau JY.
    Rev Med Suisse; 2006 May 31; 2(68):1499. PubMed ID: 16783999
    [No Abstract] [Full Text] [Related]

  • 2. [A new step towards an influenza A H5N1 vaccine].
    Nau JY.
    Rev Med Suisse; 2006 May 24; 2(67):1431. PubMed ID: 16786960
    [No Abstract] [Full Text] [Related]

  • 3. An inactivated subvirion influenza A (H5N1) vaccine.
    Johansson BE, Brett IC.
    N Engl J Med; 2006 Jun 22; 354(25):2724-5; author reply 2724-5. PubMed ID: 16790710
    [No Abstract] [Full Text] [Related]

  • 4. An inactivated subvirion influenza A (H5N1) vaccine.
    Focosi D.
    N Engl J Med; 2006 Jun 22; 354(25):2724-5; author reply 2724-5. PubMed ID: 16795150
    [No Abstract] [Full Text] [Related]

  • 5. Vaccines against avian influenza--a race against time.
    Poland GA.
    N Engl J Med; 2006 Mar 30; 354(13):1411-3. PubMed ID: 16571885
    [No Abstract] [Full Text] [Related]

  • 6. Influenza vaccine 2007-2008.
    Med Lett Drugs Ther; 2007 Oct 08; 49(1271):81-3. PubMed ID: 17912142
    [No Abstract] [Full Text] [Related]

  • 7. Pre- or post-pandemic influenza vaccine?
    Osterhaus AD.
    Vaccine; 2007 Jun 28; 25(27):4983-4. PubMed ID: 17555851
    [No Abstract] [Full Text] [Related]

  • 8. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ.
    J Infect Dis; 2008 Sep 01; 198(5):635-41. PubMed ID: 18694338
    [Abstract] [Full Text] [Related]

  • 9. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H, Liu XF, Zhang X, Chen S, Sun L, Lu J.
    Vaccine; 2007 Oct 16; 25(42):7379-84. PubMed ID: 17870216
    [Abstract] [Full Text] [Related]

  • 10. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
    Lin JT, Li CG, Wang X, Su N, Liu Y, Qiu YZ, Yang M, Chen JT, Fang HH, Dong XP, Yin WD, Feng ZJ.
    J Infect Dis; 2009 Jan 15; 199(2):184-7. PubMed ID: 19067606
    [Abstract] [Full Text] [Related]

  • 11. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS.
    Biologicals; 2008 Nov 15; 36(6):346-9. PubMed ID: 18715803
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, Kis A, Tarjan I, Rozsa N, Jankovics I.
    Pediatr Infect Dis J; 2008 Dec 15; 27(12):1052-6. PubMed ID: 18978514
    [Abstract] [Full Text] [Related]

  • 14. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T, Kawaoka Y.
    Trends Mol Med; 2006 Nov 15; 12(11):506-14. PubMed ID: 17011235
    [Abstract] [Full Text] [Related]

  • 15. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI.
    Vaccine; 2006 Nov 17; 24(47-48):6859-66. PubMed ID: 17050041
    [Abstract] [Full Text] [Related]

  • 16. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW, Sposato M, Zielinski V, Powell D, Treanor JJ, von Hofe E.
    Vaccine; 2009 Aug 27; 27(39):5393-401. PubMed ID: 19596415
    [Abstract] [Full Text] [Related]

  • 17. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
    de Jong JC, Osterhaus AD.
    Ned Tijdschr Geneeskd; 2008 Sep 27; 152(39):2113-5. PubMed ID: 18856026
    [Abstract] [Full Text] [Related]

  • 18. [H5N1: vaccine solutions for humans and other animals].
    Durand MP.
    Bull Acad Natl Med; 2006 Sep 27; 190(4-5):963-72. PubMed ID: 17195620
    [Abstract] [Full Text] [Related]

  • 19. Vaccines against influenza A (H5N1): evidence of progress.
    Poland GA, Sambhara S.
    J Infect Dis; 2008 Sep 01; 198(5):629-31. PubMed ID: 18694337
    [No Abstract] [Full Text] [Related]

  • 20. Influenza: a case for an improved link between vaccine research and public health.
    Palache AM.
    Immunol Lett; 2009 Feb 21; 122(2):137. PubMed ID: 19100772
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.